Tags

Type your tag names separated by a space and hit enter

COVID-19 and coagulative axis: review of emerging aspects in a novel disease.
Monaldi Arch Chest Dis. 2020 May 19; 90(2)MA

Abstract

Latest evidences from literature suggest that SARS-CoV-2 disease 2019 (COVID-19) is commonly complicated with coagulopathy and that disseminated intravascular coagulation is present in the majority of deceased patients. Particularly, conventional coagulation parameters appear to be significantly altered in patients with poor prognosis. A wide-ranging cross- talk between coagulative haemostasis and inflammation, as well as the activation of coagulation cascade during viral infections, are well established. Another important evidence which may explain coagulation disorders in COVID-19 is the increase of thrombus formation under conditions of hypoxia. Despite the exact pathophysiological mechanism of coronavirus-induced thromboembolism needs to be further investigated, this finding suggests that it is good practice to assess the risk of thrombosis in COVID-19 patients to improvethe clinical management in terms of anticoagulation therapy. Anticoagulants, mainly low-molecular-weight heparin (LMWH), should be tailored in patients meeting sepsis induced coagulopathy (SIC) criteria or with markedly elevated D-dimer. In this context, further studies are needed to optimise the decision making in therapeutic approach.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Boccia M
Department of Translational Medical Sciences, University of Campania "L. Vanvitelli", Naples. bocciamatilde@gmail.com.
Aronne L
Department of Translational Medical Sciences, University of Campania "L. Vanvitelli", Naples. luigi.aronne@gmail.com.
Celia B
Department of Translational Medical Sciences, University of Campania "L. Vanvitelli", Naples. benito.celia@studenti.unicampania.it.
Mazzeo G
Department of Translational Medical Sciences, University of Campania "L. Vanvitelli", Naples. grazia.mazzeo@studenti.unicampania.it.
Ceparano M
Department of Translational Medical Sciences, University of Campania "L. Vanvitelli", Naples. maria.ceparano@studenti.unicampania.it.
D'Agnano V
Department of Translational Medical Sciences, University of Campania "L. Vanvitelli", Naples. v.dagnano@studenti.unimol.it.
Parrella R
Department of Infectious Diseases, COVID Unit D, Cotugno Hospital, A.O.R.N. dei Colli, Naples. rob.parrella@gmail.com.
Valente T
Department of Radiology, Monaldi Hospital, A.O.R.N. dei Colli, Naples. tullio.valente@gmail.com.
Bianco A
Department of Translational Medical Sciences, University of Campania "L. Vanvitelli", Naples. andrea.bianco@unicampania.it.
Perrotta F
Department of Medicine and Health Sciences "V. Tiberio", University of Molise, Campobasso. fabio.perrotta@unimol.it.

MeSH

BetacoronavirusBlood CoagulationBlood Coagulation DisordersCOVID-19Coronavirus InfectionsHumansPandemicsPneumonia, ViralSARS-CoV-2

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32425013

Citation

Boccia, Matilde, et al. "COVID-19 and Coagulative Axis: Review of Emerging Aspects in a Novel Disease." Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace, vol. 90, no. 2, 2020.
Boccia M, Aronne L, Celia B, et al. COVID-19 and coagulative axis: review of emerging aspects in a novel disease. Monaldi Arch Chest Dis. 2020;90(2).
Boccia, M., Aronne, L., Celia, B., Mazzeo, G., Ceparano, M., D'Agnano, V., Parrella, R., Valente, T., Bianco, A., & Perrotta, F. (2020). COVID-19 and coagulative axis: review of emerging aspects in a novel disease. Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace, 90(2). https://doi.org/10.4081/monaldi.2020.1300
Boccia M, et al. COVID-19 and Coagulative Axis: Review of Emerging Aspects in a Novel Disease. Monaldi Arch Chest Dis. 2020 May 19;90(2) PubMed PMID: 32425013.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - COVID-19 and coagulative axis: review of emerging aspects in a novel disease. AU - Boccia,Matilde, AU - Aronne,Luigi, AU - Celia,Benito, AU - Mazzeo,Grazia, AU - Ceparano,Maria, AU - D'Agnano,Vito, AU - Parrella,Roberto, AU - Valente,Tullio, AU - Bianco,Andrea, AU - Perrotta,Fabio, Y1 - 2020/05/19/ PY - 2020/04/09/received PY - 2020/05/12/accepted PY - 2020/5/20/entrez PY - 2020/5/20/pubmed PY - 2020/5/21/medline JF - Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace JO - Monaldi Arch Chest Dis VL - 90 IS - 2 N2 - Latest evidences from literature suggest that SARS-CoV-2 disease 2019 (COVID-19) is commonly complicated with coagulopathy and that disseminated intravascular coagulation is present in the majority of deceased patients. Particularly, conventional coagulation parameters appear to be significantly altered in patients with poor prognosis. A wide-ranging cross- talk between coagulative haemostasis and inflammation, as well as the activation of coagulation cascade during viral infections, are well established. Another important evidence which may explain coagulation disorders in COVID-19 is the increase of thrombus formation under conditions of hypoxia. Despite the exact pathophysiological mechanism of coronavirus-induced thromboembolism needs to be further investigated, this finding suggests that it is good practice to assess the risk of thrombosis in COVID-19 patients to improvethe clinical management in terms of anticoagulation therapy. Anticoagulants, mainly low-molecular-weight heparin (LMWH), should be tailored in patients meeting sepsis induced coagulopathy (SIC) criteria or with markedly elevated D-dimer. In this context, further studies are needed to optimise the decision making in therapeutic approach. SN - 1122-0643 UR - https://www.unboundmedicine.com/medline/citation/32425013/COVID_19_and_coagulative_axis:_review_of_emerging_aspects_in_a_novel_disease_ DB - PRIME DP - Unbound Medicine ER -